← Back to Clinical Trials
Recruiting NCT06964867

NCT06964867 Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06964867
Status Recruiting
Phase
Sponsor Changzhou No.2 People's Hospital
Condition Vitreous Floaters
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2023-12-01
Primary Completion 2025-06-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Multimedia Health Education

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2023-12-01 with a primary completion date of 2025-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The patients with vitreous floaters were randomly divided into to groups after excluding the possibility of coexisting ocular pathologies potentially confounding visual symptoms or vitreoretinal anatomy. The control group performed conventional oral education. The experimental group conducted multimedia health education activities on the basis of conventional oral education. Their VRQoL (Visual Function Questionnaire-25, VFQ-25) and anxiety status (State-Trait Anxiety Inventory, STAI) were evaluated before education and at the final follow-up. The demographic and clinical characteristics (gender, age, eduaction, duration of vitreous floaters, comorbidities and so on) were collected.

Eligibility Criteria

Inclusion Criteria: 1. Clinical diagnosis of vitreous floaters; 2. Be able to complete questionnaires. Exclusion Criteria: 1. Secondary VF requiring surgical intervention; 2. Coexisting ocular pathologies potentially confounding vitreoretinal anatomy; 3. History of vitreoretinal surgery.

Contact & Investigator

Central Contact

Qing Feng

✉ fengqing20001128@163.com

📞 15098912007

Frequently Asked Questions

Who can join the NCT06964867 clinical trial?

This trial is open to participants of all sexes, studying Vitreous Floaters. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06964867 currently recruiting?

Yes, NCT06964867 is actively recruiting participants. Contact the research team at fengqing20001128@163.com for enrollment information.

Where is the NCT06964867 trial being conducted?

This trial is being conducted at Changzhou, China.

Who is sponsoring the NCT06964867 clinical trial?

NCT06964867 is sponsored by Changzhou No.2 People's Hospital. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology